Dr. Wang on Unique Properties of KTE-X19 in Relapsed/Refractory MCL
Michael Wang, MD, discusses unique properties of the investigational CAR T-cell therapy KTE-X19 in relapsed/refractory mantle cell lymphoma.
Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses unique properties of the investigational CAR T-cell therapy KTE-X19 in relapsed/refractory mantle cell lymphoma (MCL).
In February 2020, the FDA granted a priority review designation to a biologics license application for KTE-X19 for the treatment of adult patients with relapsed/refractory MCL.
In the phase 2 ZUMA-2 trial, a single infusion of KTE-X19 elicited a 93% objective response rate and a 67% complete response rate.
KTE-X19 utilizes the costimulatory molecule CD28, whereas other novel CAR T-cell therapies use the costimulatory signal 4-1BB.
Pending approval, KTE-X19 could be used following BTK inhibition in patients who do not respond to BTK inhibitors or in patients with high-risk disease who respond for a short duration of time, concludes Wang.
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
